BFCFSI
RARE icon

BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC.’s Ultragenyx Pharmaceutical RARE Stock Holding History

BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC.’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13
Closed -$272 – 2523
2026
Q1 		$272 Hold
13
– – ﹤0.01% 2386
2025
Q4 		$299 Hold
13
– – ﹤0.01% 2486
2025
Q3 		$391 Buy
+13
New +$390 ﹤0.01% 2336

Other funds holding RARE

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $24.8B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC.'s RARE Position: Q2 2026 in Review

BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC. sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 13 shares — an estimated $272 sold.

BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC. first reported a position in RARE in Q3 2025 and held it in 3 quarters. The position peaked at $391 in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC. reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC. sold 13 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $272.
  • BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC. first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and held it in 3 quarters.
  • BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC.'s Ultragenyx Pharmaceutical position peaked at $391 in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC.'s 13F filing for Q2 2026, filed 30 Oct 2026.